Latest Kynam Capital Management, LP Stock Portfolio
Kynam Capital Management, LP Performance:
2025 Q3: 29.73%YTD: -0.55%2024: 24.69%
Performance for 2025 Q3 is 29.73%, and YTD is -0.55%, and 2024 is 24.69%.
About Kynam Capital Management, LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Kynam Capital Management, LP reported an equity portfolio of $1.3 Billions as of 30 Sep, 2025.
The top stock holdings of Kynam Capital Management, LP are CLDX, SNDX, VERA. The fund has invested 11.8% of it's portfolio in CELLDEX THERAPEUTICS INC NEW and 9.8% of portfolio in SYNDAX PHARMACEUTICALS INC.
The fund managers got completely rid off LIQUIDIA CORPORATION (LQDA) stocks. They significantly reduced their stock positions in UROGEN PHARMA LTD (URGN), TRAVERE THERAPEUTICS INC (TVTX) and CG ONCOLOGY INC. Kynam Capital Management, LP opened new stock positions in MBX BIOSCIENCES INC, UNITED THERAPEUTICS CORP DEL (UTHR) and APELLIS PHARMACEUTICALS INC (APLS). The fund showed a lot of confidence in some stocks as they added substantially to NURIX THERAPEUTICS INC (NRIX), CYTOMX THERAPEUTICS INC (CTMX) and VERA THERAPEUTICS INC (VERA).
The top stock holdings of Kynam Capital Management, LP are CLDX, SNDX, VERA. The fund has invested 11.8% of it's portfolio in CELLDEX THERAPEUTICS INC NEW and 9.8% of portfolio in SYNDAX PHARMACEUTICALS INC.
The fund managers got completely rid off LIQUIDIA CORPORATION (LQDA) stocks. They significantly reduced their stock positions in UROGEN PHARMA LTD (URGN), TRAVERE THERAPEUTICS INC (TVTX) and CG ONCOLOGY INC. Kynam Capital Management, LP opened new stock positions in MBX BIOSCIENCES INC, UNITED THERAPEUTICS CORP DEL (UTHR) and APELLIS PHARMACEUTICALS INC (APLS). The fund showed a lot of confidence in some stocks as they added substantially to NURIX THERAPEUTICS INC (NRIX), CYTOMX THERAPEUTICS INC (CTMX) and VERA THERAPEUTICS INC (VERA).
Kynam Capital Management, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Kynam Capital Management, LP made a return of 29.73% in the last quarter. In trailing 12 months, it's portfolio return was -7.26%.
New Buys
| Ticker | $ Bought |
|---|---|
| mbx biosciences inc | 35,000,000 |
| united therapeutics corp del | 20,009,800 |
| apellis pharmaceuticals inc | 18,298,800 |
| pharvaris n v | 16,841,200 |
| kalvista pharmaceuticals inc | 7,383,160 |
New stocks bought by Kynam Capital Management, LP
Additions
| Ticker | % Inc. |
|---|---|
| nurix therapeutics inc | 84.78 |
| cytomx therapeutics inc | 69.26 |
| vera therapeutics inc | 17.54 |
| biocryst pharmaceuticals inc | 10.95 |
| cullinan therapeutics inc | 9.84 |
| beam therapeutics inc | 4.14 |
| immunocore hldgs plc | 3.38 |
Additions to existing portfolio by Kynam Capital Management, LP
Reductions
| Ticker | % Reduced |
|---|---|
| urogen pharma ltd | -56.99 |
| travere therapeutics inc | -38.36 |
| cg oncology inc | -18.41 |
| cogent biosciences inc | -7.14 |
Kynam Capital Management, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| liquidia corporation | -2,492,590 |
Kynam Capital Management, LP got rid off the above stocks
Sector Distribution
Kynam Capital Management, LP has about 86.7% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 86.7 |
| Others | 13.3 |
Market Cap. Distribution
Kynam Capital Management, LP has about 1.5% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 44.3 |
| MID-CAP | 35 |
| UNALLOCATED | 16 |
| MICRO-CAP | 3.2 |
| LARGE-CAP | 1.5 |
Stocks belong to which Index?
About 79.4% of the stocks held by Kynam Capital Management, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 79.4 |
| Others | 20.6 |
Kynam Capital Management, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Kynam Capital Management, LP
Kynam Capital Management, LP has 35 stocks in it's portfolio. About 72.6% of the portfolio is in top 10 stocks. BCRX proved to be the most loss making stock for the portfolio. COGT was the most profitable stock for Kynam Capital Management, LP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AMRN | amarin corp plc | 0.70 | 576,111 | 9,436,700 | unchanged | 0.00 | ||
| APLS | apellis pharmaceuticals inc | 1.36 | 808,607 | 18,298,800 | new | |||
| BCRX | biocryst pharmaceuticals inc | 5.31 | 9,390,270 | 71,272,200 | added | 10.95 | ||
| BEAM | beam therapeutics inc | 4.55 | 2,517,650 | 61,103,300 | added | 4.14 | ||
| BNR | burning rock biotech ltd | 0.64 | 994,883 | 8,605,740 | unchanged | 0.00 | ||
| CGEM | cullinan therapeutics inc | 1.02 | 2,302,170 | 13,651,900 | added | 9.84 | ||
| CLDX | celldex therapeutics inc new | 11.75 | 6,100,730 | 157,826,000 | unchanged | 0.00 | ||
| COGT | cogent biosciences inc | 8.43 | 7,886,170 | 113,245,000 | reduced | -7.14 | ||
| CRBU | caribou biosciences inc | 0.53 | 3,067,770 | 7,147,910 | unchanged | 0.00 | ||
| CTMX | cytomx therapeutics inc | 0.87 | 3,646,500 | 11,632,300 | added | 69.26 | ||
| DSGN | design therapeutics inc | 0.58 | 1,029,580 | 7,752,730 | unchanged | 0.00 | ||
| DVAX | dynavax technologies corp | 1.59 | 2,145,320 | 21,303,000 | unchanged | 0.00 | ||
| ELYM | climb bio inc | 0.15 | 1,028,340 | 2,066,960 | unchanged | 0.00 | ||
| EWTX | edgewise therapeutics inc | 0.31 | 253,979 | 4,119,540 | unchanged | 0.00 | ||
| GERN | geron corp | 0.35 | 3,456,320 | 4,735,160 | unchanged | 0.00 | ||
| IMCR | immunocore hldgs plc | 2.73 | 1,009,270 | 36,666,700 | added | 3.38 | ||
| IRWD | ironwood pharmaceuticals inc | 0.53 | 5,466,820 | 7,161,540 | unchanged | 0.00 | ||
| KALV | kalvista pharmaceuticals inc | 0.55 | 606,171 | 7,383,160 | new | |||
| LQDA | liquidia corporation | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| NRIX | nurix therapeutics inc | 1.49 | 2,168,600 | 20,037,900 | added | 84.78 | ||